Vaccination against Covid-19 - IgG antibodies, CIC and complement components in serum
Authors:
K. Absolonová; M. Hill; I. Šterzl
Authors‘ workplace:
Vedoucí laboratorního komplementu: Mgr. Josef Včelák
; Endokrinologický ústav, Praha
Published in:
Prakt. Lék. 2024; 104(3): 112-115
Category:
Of different specialties
Overview
In a group of vaccinated and unvaccinated individuals who did or did not experience Covid-19 disease, we monitored the relationship between anti-SARS-CoV-2 IgG and some parameters that, according to the literature, are important in the development and course of illness of Covid-19. These were total IgG, IgG1-4 subclasses, complement components C3c, C4 and circulating immune complexes (CIC). We found that unvaccinated, vaccinated with Pfizer/BioNTech and Moderna vaccine, as well as advanced and non-advanced Covid-19 patients differed significantly in the level of anti-SARS-CoV-2 IgG. Vaccination had a greater effect on the level of antibodies than experiencing the disease. IgG4 increased in vaccinees after the Pfizer/BioNTech vaccine. Other IgG subclasses, total IgG, CIC and complement components were not statistically significantly different between groups.
Keywords:
vaccination – COVID-19 – IgG – complement components – circulating immune complexes
Sources
- Dispenza MC. Classification of hypersensitivity reactions. Allergy Asthma Proc. 2019; 40(6): 470–473.
- Dobiáš M, Lami J, Bukovská L, Kořínek, J. Imunotrombóza, koagulopatie, plicní embolie a její diagnostika u COVID-19. AtheroRev. 2022; 7(1): 6–13.
- Chakraborty S, Gonzalez J, Edwards K, et al. Proinflammatory IgG Fc structures in patients with severe Covid-19. Nat Immunol. 2021; 22(1): 67–73.
- Irrgang P, Gerling J, Kocher K, et al. Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARSCoV-2 mRNA vaccination. Sci Immunol. 2023; 8(79): eade2798.
- Jarlhelt I, Nielsen SK, Jahn CXH, et al. SARS-CoV-2 Antibodies mediate complement and cellular driven inflammation. Front Immunol. 2021; 12: 767981.
- Manzo G. Covid-19 as an immune complex hypersensitivity in antigen excess conditions: theoretical pathogenetic process and suggestions for potential therapeutic interventions. Front Immunol. 2020; 11: 566000.
- Mastaglio S, Ruggeri A, Risitano AM, et al. The first case of Covid-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020; 215: 108450.
- Mücke T, Knop V, Mücke MM, et al. First description of immune complex vasculitis after Covid-19 vaccination with BNT162b2: a case report. BMC Infect Dis. 2021; 21: 958.
- Roncati L, Ligabue G, Fabbiani L, et al. Type 3 hypersensitivity in Covid-19 vasculitis. Clin Immunol. 2020; 217: 108487.
- Vaquero ST, de Campos-Mata L, Ramada JM, et al. The mRNA-1273 Vaccine induces cross-variant antibody responses to SARS-CoV-2 with distinct profiles in individuals with or without pre-existing immunity. Front Immunol. 2021; 12: 737083.
adresa pro korespondenci:
Mgr. Karolína Absolonová, PhD.
Endokrinologický ústav
Národní 8, 110 00 Praha 1
e-mail: kabsolonova@endo.cz
Labels
General practitioner for children and adolescents General practitioner for adultsArticle was published in
General Practitioner
2024 Issue 3
Most read in this issue
- Vaccination against Covid-19 - IgG antibodies, CIC and complement components in serum
- Values related to feelings of loss of dignity in patients with rheumatological diseases
- Is the different socioeconomic status of families a source of differences in physical activity, sleep, and sedentary behaviour in children 3–8-year-old?
- Current pharmacotherapy of benign prostatic hyperplasia